Empowering Change: Remarkable Strides in Breast Cancer Survival

Article by Dr. Donald Greig

Over the past four decades, breast cancer care has been transformed. Mortality fallen by around 40–60% in many high-income countries, reflecting the combined impact of earlier diagnosis and better treatments. Ten-year survival has risen from under 40% in the 1970s to roughly 75-80% for women diagnosed today. In this newsletter, I would like to explore how advances in molecular biology, together with many other innovations, have helped us reach this point.

Finding cancers earlier

One of the most powerful tools we have gained is mammographic screening. Regular screening means many cancers are now found at Stage 0 or Stage I, when they are smaller and have not yet spread, which greatly improves the chances of cure. Large studies show that women who participate in mammography programmes can lower their risk of dying from breast cancer by about one-third to two-fifths over the following decade compared with women who are not screened. Earlier diagnosis has also increased awareness, encouraging women to seek help promptly if they notice changes in their breasts.

Gentler, more precise surgery

Earlier detection and better imaging have allowed surgery to become less radical but more precise. Many women can now have breast-conserving surgery (lumpectomy) with excellent long-term control, rather than needing a mastectomy in every case. Sentinel lymph node biopsy has replaced extensive node removal for many patients, reducing the risk of long-term problems such as arm swelling (lymphoedema) while still giving surgeons the information they need to plan treatment safely.

Smarter systemic treatments

Chemotherapy, hormone therapy, and targeted therapies have all become more effective and more tailored. Drugs such as trastuzumab for HER2-positive breast cancer have markedly improved survival for women whose tumours carry this specific marker. Using chemotherapy before surgery (neoadjuvant therapy) not only shrinks tumours to make surgery easier, but also shows us in real time how well a cancer responds, helping to guide subsequent treatment choices.

The molecular biology revolution

A key reason for this progress is our deeper understanding of the molecular biology of breast cancer. We now recognise that breast cancer is not a single disease but a family of subtypes, defined by features such as hormone receptors and HER2 status, each with its own behaviour and best treatment strategy. By studying patterns of gene activity, gain or loss of specific genes, and the proteins they encode, researchers have identified molecular “signatures” that predict how aggressive a tumour is and how likely it is to return.

This knowledge has opened the door to genuinely targeted therapies. Instead of treating all breast cancers in the same way, we can direct treatment at the particular pathways a given tumour depends on, sparing more healthy cells. Examples include HER2-targeted drugs, CDK4/6 inhibitors for certain hormone-receptor-positive cancers, and PARP inhibitors for cancers linked to BRCA mutations. Multi-gene tests can now help identify women whose risk of recurrence is low enough that they may safely avoid chemotherapy, reducing side effects without compromising outcomes.

Harnessing the immune system

Immunotherapy is another exciting frontier. Checkpoint inhibitors and related drugs aim to “lift the brakes” on the immune system so it can better recognise and attack cancer cells, and they are already improving outcomes in some subtypes such as triple-negative breast cancer. While immunotherapy is not yet suitable for every patient, rapid progress in understanding tumour–immune interactions at the molecular level is guiding new, more personalised.

Ensuring progress reaches everyone

As we celebrate these advances, we must also recognise that they are not yet shared equally across the globe. In many low-income settings, breast cancer mortality remains high or is rising, often because women present with more advanced disease and have limited access to screening, pathology services, surgery, radiotherapy, and modern systemic treatments. Closing this gap will require sustained efforts in awareness, infrastructure, training, and fair access to proven.

The dramatic improvements in survival we see today are the result of countless contributions-from basic scientists decoding cancer’s molecular machinery, to clinicians refining surgery, radiotherapy, and systemic therapies, to advocates fighting for better services and earlier diagnosis. Thank you for being part of this journey, whether as a patient, family member, clinician, researcher, or supporter. By continuing to work together, we move closer to a future in which breast cancer is a far less frightening diagnosis for women everywhere.

Disclaimer: This newsletter is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider for any medical concerns.